Because TNF-α is an important driver of RA pathology, we investigated the effects of statins on TNF-α-stimulated proliferation of synovial fibroblasts. Preliminary time-course experiments ranging from 24 to 96 hours (not shown) revealed that similarly to non-treated synovial fibroblasts, those pretreated with TNF-α exhibited decreased viability in a time-dependent manner. As depicted in Figure
3, both statins were able to decrease the viability of TNF-α-stimulated RA synovial fibroblasts (
n = 6). In TNF-α-stimulated RA synovial fibroblasts, simvastatin caused a marked reduction in synovial fibroblast viability compared with atorvastatin both at 3 μM (35 ± 11% versus 67 ± 13%, respectively;
p = 0.0008) and at 10 μM (2 ± 5% versus 23 ± 6%, respectively;
p = 8 × 10
-5). Reduced RA synovial fibroblast viability was observed in TNF-α-stimulated cells compared with unstimulated cells at 10 μM for both simvastatin (
p = 0.003) and atorvastatin (
p = 0.02). As with unstimulated OA synovial fibroblasts, simvastatin reduced the viability of TNF-α-stimulated OA synovial fibroblasts (
n = 6) to a greater extent than atorvastatin, but no statistically significant differences were observed at 3 μM. In contrast with RA synovial fibroblasts, there were no differences between TNF-α-stimulated and unstimulated OA synovial fibroblasts with either statin at 3 μM or 10 μM. There was a significant difference in reduction in viability between TNF-α-stimulated RA synovial fibroblasts compared with OA synovial fibroblasts at 10 μM, both with simvastatin (
p = 0.02) and with atorvastatin (
p = 0.007). These differences were not explained by differences in the degree of stimulation of OA and RA synovial fibroblasts to TNF-α (
p = 0.72 for the atorvastatin control;
p = 0.33 for the simvastatin control). Taken together, these results show that although TNF-α stimulates OA and RA synovial fibroblasts equally, RA synovial fibroblasts show a further decrease in viability in the presence of statins.